Gary Fanger, PhD – Founder, President and CEO

Gary Fanger has over 20 years of experience in the biotechnology industry developing novel therapeutics, establishing drug development alliances, and leading M&A activities. He serves as a director on the boards of Virtici and OncoImmune.  In his previous role as Senior Vice President & Chief Operating Officer at Amplimmune, Dr. Fanger helped to lead the $500 million acquisition by Medimmune/AstraZeneca in 2013.  Prior to joining Amplimmune, Dr. Fanger was Vice President of Business Development at MacroGenics where he directed partnering activities that included establishing MacroGenics’ strategic alliance with Eli Lilly & Company. Before MacroGenics, Dr. Fanger was responsible for a diverse array of corporate functions at Corixa Corporation, including heading up business development activities, establishing and directing the therapeutic antibody development program, and managing numerous pharma strategic alliances. Dr. Fanger has co-authored over 45 articles, book chapters, and reviews in peer-reviewed journals in the areas of molecular biology, cell biology, and drug development research. He has also been awarded 35 patents. Dr. Fanger received his MBA from Seattle University, PhD in Molecular and Cellular Biology from Dartmouth Medical School, and his BS in Chemistry from Denison University.

Neil Fanger, PhD – Founder and Board Member

Neil Fanger has over 17 years of experience in the life sciences industry, spanning business development, product strategy, and biological research. He is currently CEO of Virtici, a product development company that works closely with leading scientific investigators and their respective research institutions to commercialize innovations. As CEO, he has helped establish business affiliates in Boston, MA (Celdara) and Indianapolis, IN (MBV), and pipeline development partners, such as Daiichi Sankyo. Prior to Virtici, Dr. Fanger co-founded Teranode Corporation (acquired by Rage Frameworks in 2010). At Teranode, he led teams that introduced new products into the marketplace and secured worldwide partnerships with strategic customers such as Pfizer, AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline. Prior to Teranode, Dr. Fanger focused on product development at Corixa and Immunex. Dr. Fanger is co-inventor on several patents covering novel biological therapeutics and software technologies, and co-author on numerous research publications in leading scientific journals. He earned a PhD in physiology from Dartmouth Medical School, and a BS in chemistry from Denison University.

David Pascual, PhD – Scientific Founder

Dr. Pascual is Professor of Immunology in the Department of Infectious Disease and Pathology at the University of Florida. As a mucosal immunologist, research in his laboratory is focused on understanding host mucosal responses and the basic tenets of mucosal immunology.  Dr. Pascual has spent the last 26 years developing and testing various therapeutic approaches for preventing and treating autoimmune and infectious diseases, as well as technology applications to improve drug development.  His research has resulted in a variety of discoveries that are seminal in the context of the foundation technology supporting Rise Therapeutics. Dr. Pascual has published over 130 peer-reviewed publications, has several patents, is an editor of Clinical & Vaccine Immunology, serves on the editorial board for Infection and Immunity, as well as past Mucosal Immunology Section Editor for The Journal of Immunology.  Dr. Pascual is regularly sought by agency review panels for his expertise in mucosal immunology, infectious diseases, and autoimmunity. Dr. Pascual was tenured at Montana State University and left as a full professor in 2012 to the University of Florida where he is currently tenured.  Dr. Pascual graduated with M.S. and PhD degrees in microbiology from the University of Mississippi Medical Center.